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Abstract: Cognitive impairment is currently considered a core feature of schizophrenia (SZ) and
is gaining attention as a fundamental therapeutic target. Standard treatment for SZ involves the
use of antipsychotics that are successfully used to control positive symptoms and disorganized
behaviour. However, it is still unclear whether they are effective on social cognition (SC) impairment.
Furthermore, different medications are currently being studied to improve SC in patients with SZ. A
literature search on this topic was conducted using the PubMed database. All kinds of publications
(i.e., reviews, original contributions and case reports) written in English and published in the last
15 years were included. The aim of our literature review is to draw a picture of the current state of
the pharmacological treatment of SC impairment in SZ.
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1. Introduction
Schizophrenia (SZ) is a major psychiatric disorder. It is characterized by the disruption
of various mental processes, including the perception of reality, emotions and cognition.
Standard treatment involves the use of antipsychotics that are successfully used to control
positive symptoms and disorganized behaviour. However, cognitive impairment, especially
social cognition (SC), is gaining attention and is considered by some psychiatrists as the core
feature of SZ; for these clinicians, future treatments should target SC deficits as important
limits for recovery from SZ.
Historically, it can be argued that cognition has been a focus for researchers since
Bleuler, Kraepelin and Jaspers over 100 years ago [1–3]; however, it started to be the
target of pharmacological and psychosocial treatment in more recent years. Over the
past two decades, research on cognition in SZ has widely expanded, highlighting new
important information about this illness. First, between 75 and 85% of patients with SZ
show low cognitive performance and, interestingly, their family members also exhibit mild
cognitive impairment [4,5]. Second, Reichenberg and colleagues [6] pointed out that the
impairment of certain cognitive domains is present in the prodromal phase of SZ before the
onset of psychotic symptoms and it progressively worsens over the course of the illness.
Furthermore, according to Green and colleagues [7], the degree of cognitive impairment
directly reflects the future functional outcome of patients with SZ.
Cognition has two branches: neurocognition (NC) and SC. NC includes mental abili-
ties such as working memory, learning and memory, attention, processing speed, reasoning
and problem solving [8]. For a long time, NC has been considered the main predictor
of functional outcomes [9–11]. However, the other branch, SC, is gaining considerable
attention. It refers broadly to the high mental processes involved with perception, stor-
age and the use of social information that helps everyone to make sense of themselves
and others. Increasing evidence highlights that SC is also a direct predictor of functional
outcomes, particularly of community and social functioning such as to fulfil basic social
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roles and being involved in social relationships [12]. NC and SC are interlinked. Indeed,
SC may act as a mediator between basic neurocognition and daily life functioning [13,14].
Several studies, by using path analysis and structural equation modelling, have highlighted
that the explanation of functional outcome variance of patients with SZ depends more
on SC than on NC [13,15–19]. Moreover, social neuroscience studies of SZ have shown
functional and structural abnormalities in brain areas associated with specific social cogni-
tive domains [20]. These findings directed researchers toward specific treatments for the
impairment of SC in order to obtain functional changes in the daily life of patients with
SZ [21].
Numerous psychosocial interventional approaches have been developed with the
aim of improving aspects of SC [22,23]. At first, training for SC was embedded among
treatment for neurocognition and this resulted in difficulties in understanding whether
the improvement on SC was specifically due to social cognitive tasks or to the global
approach. Broad-based interventions included SC training within broad psychosocial
approaches [24–26].
For example, social skills training, which is one of the most employed training for
SC, does not consist of specific practices for implementing underutilized social cognitive
processes as it helps individuals to acquire and practice specific behavioural skills in social
interactions. A few treatment packages have included SC training exercises as one element
of much broader training programs: Integrated Psychological Therapy [27] and Cognitive
Enhancement Therapy [28] are multi-element treatment packages that includes extensive
SC training along with cognitive remediation and social skills training. They both revealed
moderate effects on SC outcomes [29]. The first one affirms that basic NC deficits have a
pervasive effect on higher levels of behavioural organization, including social skills and
social functioning [30], while the second one is based on the hypothesis that NC deficits in
several cognitive clusters caused impairment on encoding, remembering, interpreting and
responding to subtle cues regarding context-specific rules or affect [31,32].
Recent broad-based interventions incorporate novel techniques (computerized train-
ing, online training programs and virtual reality), are shorter in duration and do not target
specific social cognitive domains [26]. This type of social cognitive training focused on
the extended practice of elementary social cognitive skills programs and has provided
satisfactory results with respect to both SC and social functioning.
Later on, researchers concentrated on specific social cognitive domains, demonstrating
that it was possible to improve performance on social cognitive tasks. A series of targeted
interventions are focused on delivery of SC treatment without any other intervention
components. An example is the Cognitive Remediation (CR), which boosts information
processing skills as a means of indirectly improving social functioning. CR is defined
as “a behavioural training-based intervention that aims to improve cognitive processes
(attention, memory, executive function), social cognition and metacognition, with the goal
of durability and generalization” (Cognitive Remediation Experts Workshop (Florence,
Italy, April 2010)) [33]. It is based on targeted training strategy that could be personalized.
CR and targeted interventions, in general, have reported positive outcomes in improving
SC, particularly in the domains of emotion processing and theory of mind, but their effects
on social functioning have not been universally confirmed [26]. Recently, comprehensive
training with tasks of multiple social cognitive domains have been designed and obtained
promising results [34].
It remains an open question whether the psychopharmacological approach is a viable
solution to treat cognitive impairment. Due to the complexity of understanding the
biological bases of SC, the development of pharmacological intervention is still limited.
Therefore, both basic and clinical research are now focusing on this topic. The aim of our
literature review is to draw a picture of the current state of pharmacological treatment for
SC impairment in SZ. In order to do so, we first presented a quick overview on what SC is,
how it is assessed, its impairment and its neural correlates. Then, we focused on exploring
the current ideas on pharmacological treatment of social cognitive impairment in SZ.
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2. Overview of Social Cognition in Schizophrenia
2.1. Social Cognition
SC refers to psychological processes involved in the perception of social signals and
in the connection of such perception to motivation, emotion and adaptive behaviour.
It allows people to recognize, manipulate and behave with respect to socially relevant
information. According to Adolphs [35] “Social cognition guides both automatic and
volitional behaviour by participating in a variety of processes that modulate behavioural
response: memory, decision-making, attention, motivation and emotion are all prominently
recruited when socially relevant stimuli elicit behaviour.”
At the National Institute of Mental Health workshop in 2006 [36] it was stated that SC
includes five principal domains: Theory of Mind, emotional processing, social knowledge,
social perception and attribution bias.
1. Theory of Mind (ToM): ToM is the ability to attribute mental states, such as desires,
intentions and beliefs, to others and to understand that others have beliefs that are
different from one’s own [21]. Skills that help to understand the intentions of others,
such as non-verbal communications and sarcasm, are included in ToM [37]. Deficits
in ToM may cause misreading of intentions, emotions or cues from others, with
consequent difficulties in social communication and limited expression of empathy
toward others. Later, the study of ToM has been extended to SZ patients based on
evidence that alterations in SC may play a key role in the pattern of their clinical
symptoms [38]. In the early 1990s, studies conducted by Frith and colleagues [39,40]
and by Corcoran [41] supposed that the deficit of people with SZ in the understanding
of oneself and the mental states of others underlying overt behaviour (i.e., ToM or
mentalization deficit) resulted in the inability in creating metarepresentations that
correctly attribute thoughts to others. According to these authors, this difficulty would
represent a core feature in the genesis of psychotic symptoms, therefore ascribing
mentalization processes a key role in the psychopathology of SZ [42,43].
2. Emotional processing: Emotional processing is the ability to perceive and use emo-
tions. It defines the emotional intelligence of an individual and includes the capacity
to identify, understand and manage emotions [44].
3. Social knowledge: Social knowledge is the awareness of the rules that define interper-
sonal relationships in society [45]. It is fundamental for people to reach adequate social
competence [46], defined as the capacity to solve interpersonal problems through
verbal and non-verbal communication [47].
4. Social perception: Social perception is the ability to identify, understand and employ
social cues, roles and rules to make inferences about context, relationship and social
situations using verbal and non-verbal communication [48]. It allows people to form
impressions of others from elements of social interaction [49].
5. Attribution bias: According to Kelley [50], human behaviour can be usually attributed
to internal factors, such as one’s will and intentions; or to external factors, such as
situations. Using causal attribution human beings judge or infer reasons for the
behaviour or social situations of others. An attribution bias is an error in attributing a
cause to internal or external factors.
2.2. Assessment of Social Cognition in SZ
In 2003, the National Institute of Mental Health (NIMH) established the Measurement
and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative to
clarify the main concepts and evaluation criteria associated with NC and SC relative to
people living with SZ. The goal of the MATRICS consensus conference (MCC) was two-fold:
First, to identify cognitive domains worthy of attention in a consensus cognitive battery;
second, to establish criteria for selections of the battery tests [51]. SC was included as one
of the seven domains represented in the MCC Battery (MCCB) for clinical trials in SZ and
the Managing Emotions component of the Mayer–Salovey–Caruso Emotional Intelligence
Test (MSCEIT) was selected [36,52].
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There are other tests used to assess the specific domain of SC, such as difficulty
in recognizing facial emotion. For example, Facial Emotion Discrimination test, Facial
Emotion Identification Test (FEIT) [53] and Penn Emotion Recognition Test (ER-40) [54].
The ER-40 is considered a promising tool to evaluate emotion identification and response in
SZ [55]. In addition, the Bell Lysaker Emotion Recognition Task (BLERT) evaluates emotion
processing through the recognition of seven emotional states [56].
The Awareness of Social Inference Test (TASIT) is a ToM test designed with seven
scales: positive emotions, negative emotions, sincere, simple sarcasm, paradoxical sarcasm,
sarcasm enriched and lie. The scales are organized into three sections: emotion recognition,
social inference minimal and enriched [57].
Mental state attribution can also be investigated through the Reading the Mind in the
Eyes Test (Eyes) and the Hinting Task. Eyes focuses on the capacity of understanding the
mental states of others from expressions in the eye region of the face [58]. Hinting Task
focuses on the ability to infer the true intent of indirect speech [41].
The Social Cognition Screening Questionnaire (SCSQ) is designed to assess multiple
domains of SC, especially ToM, metacognition and hostility bias. The SCSQ presents
interpersonal vignettes that describe ambiguous interpersonal situations and the subject is
requested to answer yes/no questions. Moreover, the SCSQ can assess non-SC as schematic
inference and verbal memory [59,60].
The Intentional Bias Task (IBT) evaluates the tendency to attribute intentionality to
the actions of others. Patients are asked to define action as occurred “on purpose” or “by
accident” [61].
The Mini Profile of Nonverbal Sensitivity (MiniPONS) and The Social Attribution
Task-Multiple Choice version (SAT-MC) are used to assess social perception by decoding
interpersonal cues [62,63].
Even though these tools are currently used to evaluate SC in SZ, it can be argued that it
is still missing a strong validation of measures to assess SC and this represents a significant
limitation for clinical trials [64]. The Social Cognition Psychometric Evaluation (SCOPE)
study was designed to reduce this limitation [64,65] by systematically evaluating the psy-
chometric properties of promising measures. It was a five-phase project that ultimately
focused on the following tasks: BLERT, ER-40, Eyes, TASIT, Hinting Task, MiniPONS,
SAT-MC and IBT. According to its results, the BLERT, Hinting Task and ER-40 are recom-
mended for use in trials as they possessed the strongest psychometric properties; Eyes, IBT
and TASIT require further study as they possessed weaker psychometric properties; and
MiniPOS and SAT-MC have poorer psychometric properties.
2.3. Social Cognition Deficit in Schizophrenia
SZ patients show meaningful deficits in different dimensions of SC [66]. These deficits
are considered core features of SZ and seem to be present throughout the course of the
disease from the prodromal phase in high-risk subjects, in the first stages of the illness and
during symptom remission. They were also demonstrated in first-degree relatives of SZ
patients [13,67–70]. These findings suggest that SC deficits are unlikely to be an undesirable
effect of taking psychoactive medication [71].
Recently, a comprehensive review of SC in first episode psychosis (FEP) examined
48 relevant studies and showed consistent SC deficits in individuals who experienced a
FEP, particularly in emotional processing and ToM [72]. Furthermore, SC deficits appear to
be stable over time in FEP samples and comparable with SZ clinical groups.
According to Galderisi and colleagues [73] and previous studies [14,74], the impair-
ment of SC in patients with SZ could be a mediator of the relationship between NC and
functioning. Furthermore, according to the meta-analysis of Fett and colleagues [13], SC,
as compared to NC, could have a stronger connection to functional outcome.
Recently, Rocca and colleagues [75] conducted a study that stratified the functional
outcomes of patients with SZ on the basis of their impairment in SC. They used a large
patient sample recruited in the context of the Italian Network for Research on Psychoses
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(NIRP). A total of 809 patients with SZ completed the SC assessments that included
MSCEIT, TASIT and FEIT. It also evaluated NC, psychopathology, real life functioning and
the milestones reached. With cross-sectional data, they identified three clusters based on
SC: unimpaired (42%), impaired (50.4%) and very impaired (7.5%). Their findings showed
that real life functioning worsened significantly from the unimpaired to the impaired and
very impaired cluster, denoting a strong correlation between SC and functioning.
2.4. Neuroanatomical Substrates of Social Cognition in Healty Subjects and in Peolple with SZ
About thirty years ago, Brothers was the first to define the existence of a “social
brain”. He sustained that the network by which social knowledge operates is different
from that of other types of knowledge [76]. Studying primates, he suggested that the
“social brain” consists of three regions: the amygdala, the orbitofrontal cortex and the
temporal cortex. Thanks to functional neuroimaging, particularly functional magnetic
resonance imaging (fMRI), more brain areas were added to the “social brain”: the medial
prefrontal cortex (MPFC), the inferior frontal gyrus (IFG), the interparietal sulcus, the
inferior parietal lobule (IPL), the anterior insula (AI), the anterior cingulate cortex (ACC),
the posterior cingulate cortex/precuneus (PCC/PC) and the amygdala (Amy) [38,77–79].
Furthermore, specific areas of the temporal cortex were found to be involved in fMRI SC
tasks: the temporoparietal junction (TPJ), the posterior superior temporal sulcus (p-STS)
and the fusiform gyrus (FFG). In addition to these areas, the mirror neuron system (MNS)
is considered part of the “social brain” [80] and is embedded in the IFG, in the ventral
and dorsal premotor areas, in the supplementary motor area, in the STS, in the primary
motor cortex, in the primary somatosensory cortex, in the posterior middle temporal gyrus
(p-MTG), in the fusiform face area (FFA), in the IPL, in the middle temporal area (MTG)
and in the AI [78,81–83].
Individually, these areas play a role that cannot be considered as purely social; how-
ever, together they shape the complexity of our social interactions. Among a wide range
of skills, the “social brain” is responsible for the ability to assign emotional value to faces,
to interpret expressions as fear and distrust, to process empathy-related stimuli and to
understand the point of view of others in complicated social situations. In particular, some
socio-cognitive tasks used in functional magnetic resonance imaging (fMRI) activate mostly
cerebral areas involved in neuro-cognitive processes, while other tasks are associated with
a higher involvement of brain area activated by affective stimuli and still others exhibit an
intermediate pattern of activations [84]. In any case, a strong activation of language-related
motor areas containing mirror neurons was found in all kinds of tasks suggesting that
motor/mirror processes take place in most experimental paradigms assessing SC [84].
Moreover, when focusing on different fMRI tasks designed to study different domains
of SC, some specificity of activated brain areas was found: ToM tasks were associated
with the activation of the TPJ, MPFC, PCC/PC and of the anterior temporal lobe (ATL);
social perception tasks with OFC, FFG and Amy activation; and social action observation
with mental imitation tasks with IPL and IFG activation. The posterior superior temporal
sulcus (pSTS) was involved in all different tasks [80]. Focusing on brain networks activa-
tion during SC fMRI task, two main types of cross-network interactions were reported:
A negative coupling (segregation) between the Default Mode Network and the Control
Network (composed by Ventral Attention, Frontoparietal and Dorsal Attention Networks)
and a positive coupling (integration) between these two networks [85] according to the
type of SC fMRI task proposed.
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Focusing on neural correlates of SC in SZ, many studies have been conducted on
people with SZ engaged in SC tasks while performing fMRI. This imaging was compared
with that of healthy controls (HC) performing the same SC task in order to assess differences
attributable to the mental disorder. From these kind of studies, PFC, FFG, right Amy, visual
processing areas, ACC, IPL and STS altered activations were found in emotion recognition,
processing and attribution tasks [86–89]; left posterior TPJ and STS were hypoactivated
during ToM tasks [88,90,91], while altered activation where found in both types of SC fMRI
tasks in the bilateral AI, in the right TPJ and in the left Amy [88]. In general, during SC fMRI
tasks, people living with SZ showed hyperactivation of brain areas not directly involved in
SC and hypoactivation of brain regions belonging to the social brain. This altered activation
could be interpreted as a possible functional neural correlate of SC deficits observed in
SZ. To confirm this speculation, further meta-analytic studies are needed to integrate this
information about brain activations with a deeper knowledge of the role of functional
networks interactions in SZ patients during standardized SC fMRI tasks exploring all the
domains of SC.
3. Materials and Methods
A comprehensive search on PubMed database for articles in English published until
30 November 2020 was conducted. Search on PubMed was selected due to greater ease of
research and greater availability of sources. Filters or MESH restrictions were not used. The
search terms included were the following: “schizophrenia”, “social cognition”, “treatment”,
“pharmacological treatment” and “antipsychotics”. The search covered the last 15 years.
Reviews, original contributions and case reports were included. The articles included
dealing with the variation of SC impairment in people living with a SZ, schizoaffective
and schizophreniform disorder after a pharmacological treatment assumption. Patients
with a short duration of illness (even drug naïve patients) and patients with a history of
chronic illness were included. Studies included evaluated at least one SC domain variation
through the use of validated scales. Treatment with antipsychotic drugs have to last at least
2 weeks at an effective dosage, with no limitation for the number of doses and duration
applied for the other drugs.
Overlapping papers, papers written in languages other than English and works that
included psychotic features associated with other diagnoses (i.e., schizotypal personal-
ity disorder, major depressive disorder and bipolar disorders with psychotic features,
substance/medication-induced psychotic disorder or psychotic disorder due to another
medical condition) were excluded. References of relevant articles from screened records
were retrieved to deepen the scope of our topic.
4. Results
Our search provided 443 results. By applying the criteria proposed, results were
reduced at 203 articles. We retrieved other four interesting articles from the references of
the screened records. As described in Figure 1, the final number of publications that were
deemed eligible for the current review was 17. Among them 2 were narrative reviews,
1 was a meta-analysis, 1 was a leading article and 13 were original contributions (RCTs or
observational studies). Table 1 shows the main characteristics and findings of the original
contributions. No suitable case reports were found.
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Figure 1. Flow chart of the search and selection of the literature reports.
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Table 1. Original contributions about studies that investigate pharmacological treatment in SZ in relation to SC impairment.
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Table 1. Cont.
Study Sample Charateristics Study Design Treatment, Dose,Duration Time of Assessment SC Measures Main Findings about SC
[97]
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Table 1. Cont.











Single dose of 40 IU
intranasal oxytocin





baseline, 1 week and 1




Battery (MCCB); The Awareness
of Social Inference Test (TASIT);
Half Profile of Nonverbal
Sensitivity (Half-PONS); Facial
affect recognition from the
standardized stimulus set






OT improvement across the
combined-treatment groups;
significant main effects of time
on individual measures of facial
affect recognition, the MSCEIT
Managing Emotions total score















Single dose of 24 IU
intranasal oxytocin
(OT) spray + placebo
spray 2 weeks later




Paralanguage and face subtasks
of the Diagnostic Analysis of
Non-Verbal Accuracy (DANVA);
Facial Expressions of Emotions
Task (FEEST); Reading the Mind
in the Eyes Task (RMET); Facial
affect recognition from the
standardized stimulus set
developed by Ekman; False
Belief Picture Sequencing Task
(FBPSTL); Hinting Task; The
Faux Pas Recognition Task
OT significantly improves
higher order social cognition
performance above placebo.
Most improvement on tests
measuring appreciation of













Daily 24 IU oxytocin
(OT) nasal spray




(MSCEIT); the Reading the
Mind in the Eyes task (RMET);
Emotional Priming Paradigm
(EPP)
Significant effect of OT at
MSCEIT battery, between anger
and happiness recognition RTs
and a significant facilitation
effect
Int. J. Mol. Sci. 2021, 22, 7457 11 of 21
Table 1. Cont.
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requiring hospitalization.
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5. Discussion
Discussion is presented for every class of molecule exprerimented to improve SC
in SZ.
5.1. Antipsychotics
Currently, antipsychotics are the main treatment for SZ. Several studies have specifi-
cally deepened the effects of these drugs (particularly, the second-generation antipsychotics)
on SC impairment.
The mechanism of antipsychotics effects on SC is mostly unknown.
Second-generation antipsychotic drugs modulate dopamine neurotransmission and
act as antagonists on serotonin 2A receptors (5-HT2AR). Inhibition of the 5-HT2AR sero-
tonin receptors that are present on the cell bodies of dopaminergic neurons in the substantia
nigra and ventral tegmentum may decrease dopamine release. Furthermore, projections
of 5-HT2AR pyramidal neurons in the medial prefrontal cortex act as the modulator of
mesocortico-limbic dopaminergic neurons [105]. In fact, they would follow the functional
antagonism in the mesocortical pathway where the excess of dopamine causes positive
symptoms, while the action as functional agonist in the mesocortical pathway improves
the negative symptoms [106,107].
Different drugs have different affinities for target receptors determining the possible
added desired or adverse effects of the different drugs: Multiple-acting receptor targeted
antipsychotics (MARTAs) such as clozapine, olanzapine and quetiapine bind to multiple
other neuroreceptors and have modest affinity to D2 and 5-HT2A; serotonin and dopamine
antagonists (SDAs) such as risperidone, paliperidone, sertindole and lurasidone exhibit
potent D2 and 5-HT2A antagonistic activities, with a high affinity for α1, 5-HT2C and H1
and negligible affinity for M1 receptors. Among them, risperidone presents the stronger
dopaminergic D2 (with 72–81% striatal D2 receptor occupancy at a dose range of 4 to
12 mg/day) and serotonergic 5-HT2A antagonistic activities and show high affinity to
adrenergic, 5-HT2C serotonin and H1 histamine receptors.
Finally, dopamine system stabilizers (DSSs) are partial D2, D3 and 5-HT1A-receptor
agonists either as a functional agonist or a functional antagonist and antagonists at
5-HT2A receptors.
In addition to positive symptoms, serotonin and dopamine are thought to be involved
in the improvement of SC and possible contributes to the improvement of emotional
perception and social functioning, in2 particular, through the facilitating effect of serotonin
antagonism on dopamine release in the prefrontal cortex [21,108]. Furthermore, the role
of dopamine regulation in the mesocorticolimbic system mediated by second-generation
antipsychotics could act as an emotional manager over the amygdala [109], this could
explain the efficacy of SGAs compared to first generation antipsychotics on SC [110].
Maat and colleagues [111] conducted an 8 week, randomized, multicentre and open-
label study on 80 SZ patient aged 16–50 years treated with aripiprazole (maximum dose
30 mg) or risperidone (maximum dose 6 mg). Patients of both groups of treatment ob-
tained better scores in social cognitive and neurocognitive tests at week 8 than baseline.
Aripiprazole appeared significantly superior than risperidone in reaction times for emo-
tional working memory, a specific SC task proposed by the authors. This improvement
correlated with social functioning. Mizrahi and colleagues [92] noted an improvement
in ToM after 2 weeks of administration of clozapine, risperidone, olanzapine or loxapine
in 71 patients with psychotic disorder (SZ, schizophreniform or schizoaffective disorder),
that were initially drug free. Koshikawa and colleagues [93] conducted a 6 month pilot,
open-label and randomized controlled study on 30 patients with SZ, comparing the effects
of two long-acting injection drugs, paliperidone and risperidone, on social functioning
as the primary outcome and on SC as one of the secondary outcomes. The assessment
of SC was carried out with the Social Emotional Cognition Task (SECT). Their prelimi-
nary results showed a better improvement in social functioning in patients treated with
paliperidone. Instead, there were no significant differences in terms of the SECT accuracy.
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Behere and colleagues [94] studied a sample of 25 antipsychotic-naïve patients with SZ
and assessed their ability to recognize facial emotions typically impaired in SZ before and
after a short-term exposure to risperidone (mean duration of treatment 38.2 ± 17.1 days);
they were all treated uniformly at 4 mg/day. At the follow-up assessment, facial emotion
recognition abilities were improved, especially for the emotion of disgust. Sumiyoshi
and colleague [95] studied a sample of 20 SZ patient and reported that after 6 months of
treatment with perospirone (mean dosage 18,3 mg/day), verbal SC that was evaluated by
script tasks was improved. Roberts and colleagues [96] compared the effects of olanzapine
(117 patients with a mean dose of 15.6 mg/day) and quetiapine (106 patients with a mean
dose of 455.8 mg/day) on SC and social functioning. To assess SC, they used the Social
Cue Recognition Task (SCRT) that requires participants to view short videos of four inter-
personal vignettes and answer “true” or “false” to propositions about them. Cue subscales
are the following: Low emotion vignette, concrete cues; Low emotion vignette, abstract
cues; High emotion vignette, concrete cues; and High emotion vignette, abstract cues. This
study found an improvement after 6 months of treatment in both groups; the improvement
was modest but significant in 3 out of 4 SC cue subscales (low emotion-concrete, low
emotion-abstract and high emotion-concrete). According to the Kucharska-Pietura and
Mortimer review [97], a better improvement in SC should be expected with clozapine than
with other second-generation antipsychotics.
Currently, evidence of the impact of antipsychotic drugs on SC is inconclusive. Mainly
due to inconsistencies in study designs, methodologies, standardized drug dosages, nu-
merosity of test samples and lack of long-term assessments [21,97].
5.2. Other Drugs
Raloxifene is a first-generation selective estrogen receptor modulator (SERM) that be-
haves as an agonist in the brain and bone and as an antagonist in all the other tissues [112].
The effectiveness of raloxifene treatment in man and women with SZ was first evalu-
ated on neurocognition. A randomized, double-blind and placebo-controlled crossover
trial was conducted on a sample of 98 patients with SZ or schizoaffective disorder; in
addition to their usual antipsychotic medications, they received 120 mg/day of raloxifene.
After 6 weeks of treatment, participants who have assumed raloxifene were improved in
attention/processing speed and memory [113].
The same team have subsequently evaluated the effects of raloxifene treatment at
the same dosage on SC skills [114]. Ji and colleagues conducted a randomized, double-
blind and controlled crossover trial in order to determine if and how the adjunction of
raloxifene (120 mg per day orally for 6 weeks) to standard treatment in patients with
SZ would alter the abnormal neural activity during an angry facial emotion recognition
fMRI task. According to their results, it appears that raloxifene significantly increased
the activation in the right hippocampus and left inferior frontal gyrus compared with
the placebo, suggesting that this treatment might change neural activity in brain regions
known to be associated to facial emotion recognition. More studies are needed to confirm
these preliminary findings.
Considering that abnormal activity of the GABA neurons of the prefrontal cortex
might be involved in cognitive impairment, Kimoto and colleagues found that lower
levels of GAD67 mRNA and protein have been consistently found in the dorsolateral
prefrontal cortex of subjects with SZ. Quantification of GAD67 and Zif268 mRNA levels in
dorsolateral pre-frontal cortex area in patients with schizophrenia and healthy comparison
using polymerase chain reaction showed an altered expression of the transcriptional
regulatory factor Zif268 in schizophrenia subjects that may provide a potential mechanistic
basis for impaired GABA synthesis in the illness [98].
On this basis, Buchanan [115] investigated if GABA neuroactive drugs might improve
NC and SC in SZ. Sixty-four participants with the diagnosis of SZ enrolled in a 4 week,
placebo-controlled and parallel group double-blind study to evaluate if an adjunctive
treatment with 3 mg BID or 8 mg BID of MK-0777 (a partial agonist of GABAα2/α3) to one
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second generation antipsychotic medication may improve cognitive impairments in SZ.
The MCCB was used to assess neuropsychological test performance and also the emotion
management of SC (through MSCEIT) was evaluated. No improvement was shown when
MK-0777 was administered with antipsychotic treatment. The improvement of GABA
signaling alone is probably not enough to produce an amelioration in SC [21].
5.3. Oxytocin
Despite mixed results, the most promising effort in pharmacological approaches to SC
impairment seems to be the one focused on oxytocin.
Oxytocin is an evolutionarily conserved hypothalamic neuropeptide; it counts nine
amino acids and it is very similar to vasopressin. It is synthesized in the paraventricular,
supraoptic and accessory nuclei of the hypothalamus and it is released into systemic
circulation [99].
Oxytocin receptors are typical class I G protein-coupled receptors. They need magne-
sium and cholesterol to reach a high-affinity state. The gene sequence of this receptor has
been identified also in rats, mice, pigs, bovines, sheep and monkeys and it is expressed in
several tissues other than the brain [116]. However, in the brain, few areas can be identified
with higher receptor density, specifically the nucleus accumbens and prelimbic cortex
of prairie voles, the lateral septum of montane voles and the posterior bed nucleus stria
terminalis [117,118]. It is also interesting to note that the receptor distribution is different
between males and females in montane voles [119].
Oxytocin was initially known for its role in parturition and lactation and recently it has
gained attention for being involved in regulating the social behavior of all vertebrates [8,120].
Several studies have investigated the effects of oxytocin in the central nervous system
by demonstrating its role in bonding and maternal care, aggression, fear, anxiety and
interpersonal trust [121–123]. Growing evidence suggest that oxytocin has as important
role as a modulator in cortical processing and enhances the salience of social information
by disinhibiting cortical circuits [116].
Particularly, the ability to make and maintain social bonds is fundamental to assure
reproductive success, longevity and health in social mammals, including humans. Close
social bonds are a proxy to a solid social support system. However, how oxytocin is medi-
ating these processes remains unclear [124]. Part of the explanation could be that oxytocin
reduce the stress response; in humans, Heinrichs and colleagues [125] administered a
standard psychological stress test (TSST) and showed that the presence of a friend together
with the administration of intranasal oxytocin correlated with the lowest salivary cortisol
level when compared to groups with no friend present or no oxytocin administration.
Impairment in social behavior is a core symptom of many psychiatric disorders.
Extensive evidence from studies on animal models demonstrates that oxytocin plays a key
role in social recognition and bonding. In the last decade, in human-based research, there
has been increasing interest in using oxytocin to treat social behavior deficits in psychiatric
illnesses such as autism spectrum disorder and SZ. To date, researchers have focused on
establishing the functional effects of oxytocin measuring endogenous concentrations and
observing the effects of exogenous administration [126]. Furthermore, a field of interest is
the identification of polymorphisms and epigenetic modifications of the oxytocin receptor
gene; there is evidence that both appear to be associated to a lower gene expression in
the temporal cortex and cerebellar areas in patients with autism and SZ. There is also a
reduced volume in frontal regions and temporal-limbic areas in women with SZ [127–129].
While it is true that initially researchers have focused on different disorders includ-
ing depression, anxiety and borderline personality disorder, nowadays the focus is on
autism and SZ as both the mental disorders are characterized by profound social dysfunc-
tion [130,131]. Some studies have found low levels of oxytocin concentration in blood or
cerebrospinal fluid samples of SZ patients [132–134]. SC performance is related to periph-
eral oxytocin level and so it has been proposed as a possible biomarker in at-risk states for
schizophrenia [135,136].
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Hollander and colleagues [137] were the first to experiment intravenous doses of
oxytocin in patients with autism. They described a reduction in repetitive behaviors and
an improvement in learning with regard to affective speech [138].
In the case of SZ, the intranasal administration of oxytocin to improve SC and social
functioning has yielded mixed results [12]. A number of studies have highlighted how
single or repeated intranasal doses of oxytocin can ameliorate performance in task of
social cognition.
Davis [100,139], Guastella [101], Shilling and Feifel [102] and Brambilla [140] con-
ducted studies utilizing single administration with promising results. In particular, Davis
and colleagues [100] conducted a randomized, double-blinded and placebo-controlled
clinical trial on 27 male patients with SZ. Two groups were trained: One received 40 inter-
national units of oxytocin 30 min prior to the training session and the other one received a
dose of placebo. Training sessions focused on three domains of SC: facial affect recognition,
social perception and empathy. It was a 6 weeks and 12 session training. At the end of
the training, the oxytocin group showed significantly greater improvements in empathic
accuracy than the placebo group and this better performance was maintained one month
after the last drug administration. Brambilla and colleagues [140] examined the effects of
4 months of treatment with intranasal oxytocin in 31 subjects with SZ with a randomized,
double-blind and placebo-controlled trial. Abilities of SC were tested with a battery of
tests including MSCEIT. According to their results, oxytocin improved the performance
on MSCEIT compared to placebo. These findings suggest that patients with deficits in the
ability to process social information may use oxytocin to improve the salience of social
information. Consequently, the increased salience enhances the ability to learn higher-level
socially cognitive skills.
In this review, Bartholomeusz and colleagues [136] summarize the behavioural effects
of oxytocin in schizophrenia-spectrum disorders: It comprises six studies that analyze
the effect of a single-dose intranasal oxytocin on complex SC process, including social
perception and ToM and interpersonal perception; ten trials in which short-term treatment
(2–8 weeks) with twice-daily intranasal oxytocin is compared to the placebo; and one
study [103] in which a 6 week daily intranasal treatment is combined with social cognitive
training in an early psychosis sample. This review confirms the potential efficacy of
oxytocin treatment in the enhancement of SC abilities in SZ, on the other hand it highlights
the inconsistency of the results found due to great differences in the sample characteristics,
methodology and outcome measures used in the studies analyzed.
A recent meta-analysis [104] considered 12 studies where patients with SZ were
randomized to intranasal oxytocin vs. placebo. They found that oxytocin had a significantly
greater effect on high-level SC (i.e., mentalizing and theory of mind) compared to low-level
SC (i.e., social cue perception), suggesting that this treatment might have a selective effect
on high-level SC. This result appears important to investigate a more focused target in
future studies of intranasal oxytocin.
Cacciotti-Saija and colleagues [103] failed to replicate these results in their double-
blinded randomized controlled trial using a twice-daily chronic dose of oxytocin. In
fact, they found no evidence of social cognitive improvement. An explanation of this
failing might arise from preclinical studies that highlighted that the improvement in social
behavior obtained after an acute administration of oxytocin may be lost with chronic
administration [141].
However, future studies are needed to identify the most effective treatment regimen
with oxytocin and the subtypes of patients might benefit the most from it.
6. Conclusions
SC has been recognized as a valid treatment target in SZ.
In terms of the pharmacological treatment of social cognitive impairment in patients
with SZ, the literature suffers from wide inconsistencies in study design. Most samples
are small, medications doses are not standardized and the control of clinical variables is
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often inadequate. Moreover, it is missing a wide and validated set of tests to evaluate in
the standardized manner of all SC domains.
Antipsychotics have demonstrated unreliable effects on SC. The initial enthusiasm for
new medications, such as oxytocin, raloxifene and GABA neuroactive drugs, born from
early phase studies has faded in phase III studies. Oxytocin remains the most promising
approach, but it requires further and deeper investigation.
Presently, the pharmacological enhancement of SC in SZ appears promising but is still
in its embryonic stages. It is hopeful that large-scale longitudinal investigations will clarify
the questions regarding the role of SC on severity of symptoms and real-life functioning in
patients with SZ. In order to do so, wide studies with rigorous RCT methods are required.
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